Current Report Filing (8-k)
August 23 2016 - 3:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
August 19, 2016
|
Gilead Sciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
0-19731
|
94-3047598
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
333 Lakeside Drive, Foster City, California
|
|
94404
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
650-574-3000
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 5 CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
|
(d) Appointment of a Director
At a meeting held on August 19, 2016, the Board of Directors (the Board) of Gilead Sciences,
Inc. (the Company) elected Kelly A. Kramer to the Board effective August 19, 2016. Ms. Kramer will
serve on the Audit Committee of the Board. There is no arrangement or understanding between Ms.
Kramer and any other persons pursuant to which Ms. Kramer was selected as a director, and there are
no related party transactions involving Ms. Kramer that are reportable under Item 404(a) of
Regulation S-K.
As compensation for her service on the Board and Audit Committee during the remainder of the
2016-2017 director compensation period, Ms. Kramer will receive:
(1) A pro-rated equity grant, consisting of options to purchase 5,611 shares of the Companys
common stock and restricted stock units covering an additional 1,339 shares of Companys common
stock. These grants will be made under the Companys 2004 Equity Incentive Plan.
(2) A pro-rated cash retainer in the amount of $82,246.58.
A description of the Companys 2004 Equity Incentive Plan and compensation practices for
non-employee directors can be found in our Definitive Proxy Statement filed with the Securities and
Exchange Commission (SEC) on March 28, 2016 in connection with the Companys 2016 Annual Meeting of
Stockholders. The 2004 Equity Incentive Plan is attached as an exhibit to the Companys Current
Report on Form 8-K filed with the SEC on May 13, 2013. The 2005 Deferred Compensation Plan is
attached as an exhibit to the Annual Report on Form 10-K filed with the SEC on February 27, 2009.
A copy of the Companys press release announcing Ms. Kramers election to the Companys Board
is attached as Exhibit 99.1 to this report.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
99.1
|
|
|
Press Release, issued by Gilead Sciences, Inc. on August 23, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Gilead Sciences, Inc.
|
|
|
|
|
|
August 23, 2016
|
|
By:
|
|
/s/ Brett A. Pletcher
|
|
|
|
|
|
|
|
|
|
Name: Brett A. Pletcher
|
|
|
|
|
Title: Executive Vice President and General Counsel
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on August 23, 2016
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024